The overall survival results for both chemotherapy subgroups are consistent with the results in the overall intention-to-treat population with overlapping 95% CIs for the hazard ratio and point estimates less than 1. ...post-discontinuation anticancer therapy including both chemotherapy and immunotherapy or targeted therapy, was well balanced between the treatment groups. ...as we discuss in the Article, enrichment of PD-L1 expression is known to result in comparatively increased benefit for immunotherapies across a variety of tumour types,2,3 and this was observed in KEYNOTE-859, wherein the magnitude of benefit was greater for patients with increasing PD-L1 combined positive score (CPS) values.